tetano
Editor, Senior Moderator
Int J Hematol
. 2023 Feb 9.
doi: 10.1007/s12185-022-03518-2. Online ahead of print.
Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T
Sai Ambati[SUP] 1 [/SUP], Bazga Ali[SUP] 2 [/SUP], Owen Seddon[SUP] 2 [/SUP], Andrew Godkin[SUP] 3 [/SUP], Martin Scurr[SUP] 4 [/SUP], Catherine Moore[SUP] 5 [/SUP], Clare Rowntree[SUP] 6 [/SUP], Jonathan Underwood[SUP] 7 [/SUP]
Affiliations
Abstract
SARS-CoV-2 virus is a single-stranded enveloped RNA virus, which causes coronavirus disease. Most of the immunocompetent patients with SARS-CoV-2 infection do have mild to moderate respiratory illness; however, in immunocompromised patients, the course of infection is unpredictable with high rates of infectivity and mortality. So, it is important to identify the immunocompromised patients early and establish the course of treatment accordingly. Here, we describe a 25-year-old male with background of B cell ALL, post-BMT and CAR-T therapy who received treatment with remdesivir and vaccination and was followed up for six months from the onset of symptoms to post vaccination, which showed resolution of symptoms and improvement of immunological markers. Here, we review the literature concerning the course and treatment of SARS-CoV-2 infection aimed at achieving cure in this patient.
Keywords: B cell ALL; CAR-T therapy; Post BMT; Remdesivir; SARS-CoV-2.
. 2023 Feb 9.
doi: 10.1007/s12185-022-03518-2. Online ahead of print.
Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T
Sai Ambati[SUP] 1 [/SUP], Bazga Ali[SUP] 2 [/SUP], Owen Seddon[SUP] 2 [/SUP], Andrew Godkin[SUP] 3 [/SUP], Martin Scurr[SUP] 4 [/SUP], Catherine Moore[SUP] 5 [/SUP], Clare Rowntree[SUP] 6 [/SUP], Jonathan Underwood[SUP] 7 [/SUP]
Affiliations
- PMID: 36757522
- DOI: 10.1007/s12185-022-03518-2
Abstract
SARS-CoV-2 virus is a single-stranded enveloped RNA virus, which causes coronavirus disease. Most of the immunocompetent patients with SARS-CoV-2 infection do have mild to moderate respiratory illness; however, in immunocompromised patients, the course of infection is unpredictable with high rates of infectivity and mortality. So, it is important to identify the immunocompromised patients early and establish the course of treatment accordingly. Here, we describe a 25-year-old male with background of B cell ALL, post-BMT and CAR-T therapy who received treatment with remdesivir and vaccination and was followed up for six months from the onset of symptoms to post vaccination, which showed resolution of symptoms and improvement of immunological markers. Here, we review the literature concerning the course and treatment of SARS-CoV-2 infection aimed at achieving cure in this patient.
Keywords: B cell ALL; CAR-T therapy; Post BMT; Remdesivir; SARS-CoV-2.